Findings

What do systematic reviews say?

83 questions · 88 findings · 37 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 20 · 22.7%GRADE not reported 6 · 6.8%Very low 22 · 25%Low 18 · 20.5%Moderate 13 · 14.8%High 9 · 10.2%

Foam surfaces vs reactive gel surfaces

All reported adverse events · pressure ulcer prevention

The review found no eligible studies for this question.

1 finding from 1 review

Foam surfaces for preventing pressure ulcers 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Foam surfaces vs reactive foam and gel surfaces

All reported adverse events · pressure ulcer prevention

The review found no eligible studies for this question.

1 finding from 1 review

Foam surfaces for preventing pressure ulcers 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Reactive air surfaces vs foam surfaces

All reported adverse events · pressure ulcer prevention

1 finding from 1 review

Reactive air surfaces for preventing pressure ulcers 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 72 participants
Very low

Reactive air surfaces vs reactive water surfaces

All reported adverse events · pressure ulcer prevention

The review found no eligible studies for this question.

1 finding from 1 review

Reactive air surfaces for preventing pressure ulcers 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Reactive air surfaces vs reactive gel surfaces

All reported adverse events · pressure ulcer prevention

The review found no eligible studies for this question.

1 finding from 1 review

Reactive air surfaces for preventing pressure ulcers 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Reactive water surfaces vs reactive air surfaces

All reported adverse events · preventing pressure ulcers

The review found no eligible studies for this question.

1 finding from 1 review

Alternative reactive support surfaces (non‐foam and non‐air‐filled) for preventing pressure ulcers 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Reactive fibre surfaces vs foam surfaces

All reported adverse events · preventing pressure ulcers

The review found no eligible studies for this question.

1 finding from 1 review

Alternative reactive support surfaces (non‐foam and non‐air‐filled) for preventing pressure ulcers 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Reactive gel surfaces vs reactive air surfaces

All reported adverse events · preventing pressure ulcers

The review found no eligible studies for this question.

1 finding from 1 review

Alternative reactive support surfaces (non‐foam and non‐air‐filled) for preventing pressure ulcers 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Reactive air surfaces vs foam surfaces

All reported adverse events · people with pressure ulcers

1 finding from 1 review

Beds, overlays and mattresses for treating pressure ulcers 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 156 participants
Low

Reactive water surfaces vs foam surfaces

All reported adverse events · people with pressure ulcers

1 finding from 1 review

Beds, overlays and mattresses for treating pressure ulcers 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 120 participants
Very low

Bupropion XL vs placebo

Overall rate of adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder

Bupropion XL showed no clear difference in overall rate of adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Second‐generation antidepressants for preventing seasonal affective disorder in adults 2019 · Cochrane Headline outcomes only
RR 1.02 [0.97, 1.08]
3 studies · 1048 participants
Moderate

Phentermine/topiramate vs placebo

All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension

Phentermine/topiramate may leads to higher all adverse events compared with placebo (low certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 1.13 [1.08, 1.2]
1 study · 1305 participants
Low

Naltrexone/bupropion vs placebo

All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension

Naltrexone/bupropion probably leads to higher all adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 1.69 [1.58, 1.8]
1 study · 8283 participants
Moderate

Orlistat vs placebo

All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension

It is very uncertain whether orlistat changes all adverse events compared with placebo (very low certainty).

1 finding from 1 review

Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
RR 1.13 [0.84, 1.54]
2 studies · 1386 participants
Very low

Heparin plus aspirin vs aspirin

Allergic reaction · women with persistent antiphospholipid antibodies and recurrent pregnancy loss

1 finding from 1 review

Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
GRADE not reported

Amitriptyline vs placebo

Adverse effects (drop‐outs due to adverse effects4) · adults with Major Depressive Disorder

Amitriptyline probably leads to higher overall tolerability Drop‐out due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Amitriptyline versus placebo for major depressive disorder 2012 · Cochrane Headline outcomes only
OR 4.15 [2.71, 6.35]
19 studies · 2174 participants
Moderate

Evening vs morning dosing regimen

Overall adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater

It is very uncertain whether evening changes overall adverse events compared with morning dosing regimen (very low certainty).

1 finding from 1 review

Evening versus morning dosing regimen drug therapy for hypertension 2024 · Cochrane Headline outcomes only
RR 0.89 [0.67, 1.2]
7 studies · 1541 participants
Very low

Intervention not reported

Non‐serious local adverse events (all included trials) ICH‐GCP 1997 · patients with preventing hepatitis A.

The intervention showed no clear difference in non‐serious local adverse events (all included trials) ICH‐GCP 1997 (low certainty).

1 finding from 1 review

Hepatitis A immunisation in persons not previously exposed to hepatitis A 2012 · Cochrane Headline outcomes only
RR 1.21 [0.86, 1.7]
4 studies · 1559 participants
Low

Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy

All adverse events · people with inhibitors

Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).

1 finding from 1 review

Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes only
RR 1.6 [1.08, 2.37]
1 study · 60 participants
Moderate

Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy

All adverse events · people without inhibitors

Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).

1 finding from 1 review

Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes only
RR 2.83 [1.47, 5.47]
1 study · 54 participants
Moderate